Clinical Trial

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-10; most recent amendment 2026-03-22.
Trial Details
NCT Number NCT07470840
Lead Sponsor Fujian Cancer Hospital
Conditions Locally Advanced or Metastatic Renal Cell Carcinoma
Enrollment 27 participants
Start Date 2027-02-01
Primary Completion 2029-02-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-24